GO:0070409 carbamoyl phosphate biosynthetic process: Urea Cycle and Pyrimidine Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070409 describes the enzymatic formation of carbamoyl phosphate, a high-energy intermediate required for both the urea cycle and de novo pyrimidine biosynthesis.
• In eukaryotes, mitochondrial CPS1 (carbamoyl phosphate synthetase 1) generates carbamoyl phosphate for ureagenesis, while a separate cytosolic pathway supplies pyrimidine synthesis.
• The reaction consumes two molecules of ATP, bicarbonate, and ammonia (or glutamine in prokaryotes), and is allosterically activated by N-acetylglutamate in mammals.
• CPS1 loss or silencing alters pyrimidine pools and DNA synthesis, and has been linked to cancer cell proliferation, radioresistance, and metabolic reprogramming.
• Deficiency of CPS1 causes hyperammonemia in humans and is associated with altered pyrimidine availability, making it a target for metabolic and oncology research.
• Studying GO:0070409 requires integrating genetic, biochemical, and structural approaches, including CRISPR knockout, metabolomics, and enzyme kinetics.
Description
Carbamoyl phosphate biosynthetic process (GO:0070409) is the set of biochemical reactions that produce carbamoyl phosphate, a small but critically important metabolite that serves as the entry point for nitrogen disposal in the urea cycle and for the de novo synthesis of pyrimidine nucleotides. The reaction is catalyzed by carbamoyl phosphate synthetase (CPS) enzymes, which in mammals exist as a mitochondrial isoform (CPS1) dedicated to ureagenesis and a cytosolic isoform (CPS2) dedicated to pyrimidine biosynthesis. Because carbamoyl phosphate sits at the crossroads of amino acid catabolism and nucleic acid synthesis, its production must be tightly regulated to match cellular demands for nitrogen excretion and nucleotide supply. Researchers study GO:0070409 not only to understand basic nitrogen metabolism but also because dysregulation of this pathway has been implicated in inborn errors of metabolism, cancer, and resistance to therapy. For example, CPS1 expression is required for maintaining pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells, highlighting a direct link between carbamoyl phosphate biosynthesis and tumor growth. In hepatocellular carcinoma, CPS1 deficiency promotes radioresistance through stabilization of c-Myc, further demonstrating the clinical relevance of this pathway. This article provides a research-grade overview of GO:0070409, covering its definition, molecular mechanism, key genes, regulatory features, disease associations, and the experimental models and methods used to study it. All statements are grounded in the verified literature listed at the end.
carbamoyl phosphate biosynthetic process At A Glance
| GO ID | GO:0070409 |
|---|---|
| GO term | carbamoyl phosphate biosynthetic process |
| Ontology | biological_process |
| Synonym | carbamoyl phosphate anabolism; carbamoyl phosphate biosynthesis; carbamoyl phosphate formation; carbamoyl phosphate synthesis; carbamyl phosphate biosynthetic process |
| Major function | Production of carbamoyl phosphate for urea cycle and pyrimidine biosynthesis |
| Key enzymes | CPS1 (mitochondrial), CPS2 (cytosolic), and bacterial/archaeal CPS homologs |
| Substrates | Bicarbonate, ammonia or glutamine, ATP |
| Pathway context | Urea cycle, de novo pyrimidine biosynthesis, arginine biosynthesis |
| Cellular location | Mitochondrial matrix (CPS1) and cytosol (CPS2) in eukaryotes |
What Is GO:0070409?
GO:0070409, carbamoyl phosphate biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of carbamoyl phosphate, an intermediate in the urea cycle and other nitrogen compound metabolic pathways. In practical terms, it encompasses the enzymatic steps that convert bicarbonate, ammonia (or glutamine), and ATP into carbamoyl phosphate, a molecule that can then be used either for arginine and urea production or for pyrimidine ring assembly.
Why Is carbamoyl phosphate biosynthetic process Important in Cell Biology?
Carbamoyl phosphate biosynthesis is essential for nitrogen homeostasis and nucleotide metabolism. In mammals, CPS1 deficiency causes hyperammonemia, a life-threatening condition, while altered CPS1 expression is increasingly recognized in cancer metabolism and therapy resistance. The pathway also represents a metabolic vulnerability in certain tumors, where pyrimidine supply depends on CPS1 activity. Understanding GO:0070409 therefore has direct implications for inherited metabolic disorders, oncology, and the development of targeted therapies.
• Provides carbamoyl phosphate for the urea cycle, enabling safe disposal of excess nitrogen as urea.
• Supplies the pyrimidine ring precursor for de novo synthesis of UMP, CTP, and dTTP, impacting DNA and RNA synthesis.
• CPS1 deficiency leads to hyperammonemia and is a target for gene and small-molecule therapies.
• CPS1 expression supports pyrimidine pools and proliferation in KRAS/LKB1-mutant lung cancer.
• Loss of CPS1 promotes radioresistance in hepatocellular carcinoma via c-Myc stabilization.
• The pathway is allosterically regulated by N-acetylglutamate in mammals, linking amino acid availability to flux.
• Bacterial and archaeal CPS enzymes channel carbamoyl phosphate to arginine and pyrimidine pathways, informing antimicrobial targets.
• Enzyme channeling and substrate tunneling are paradigms for understanding metabolic efficiency.
• Cytosolic and mitochondrial carbamoyl phosphate pools are distinct and differentially regulated.
• Genetic and biochemical studies in model organisms have defined the genes and regulatory logic of the pathway.
What Happens During carbamoyl phosphate biosynthetic process?
Substrate Binding and Activation
In simple terms: The enzyme grabs bicarbonate and ATP to start making carbamoyl phosphate.
The first step involves binding of bicarbonate and ATP to the CPS active site, followed by phosphorylation of bicarbonate to form carboxyphosphate, a reactive intermediate. Ammonia (or glutamine in some organisms) then attacks carboxyphosphate to generate carbamate. This step is conserved across CPS enzymes and is essential for the overall reaction. In mammals, CPS1 uses ammonia as the nitrogen donor, while CPS2 and many microbial CPS enzymes use glutamine, which is hydrolyzed to glutamate and ammonia within the active site.
Formation of Carbamoyl Phosphate
In simple terms: The enzyme uses a second ATP to attach the carbamate to phosphate, making carbamoyl phosphate.
The carbamate intermediate is subsequently phosphorylated by a second molecule of ATP to yield carbamoyl phosphate. This step is highly endergonic and requires the energy of ATP hydrolysis. The overall reaction consumes two ATP molecules per carbamoyl phosphate produced. Structural and kinetic studies have revealed that the enzyme undergoes large conformational changes to bring the intermediates into proximity, a process often described as a molecular tunnel or channel.
Channeling to Downstream Pathways
In simple terms: The newly made carbamoyl phosphate is passed directly to the next enzyme in the pathway.
In many organisms, carbamoyl phosphate is channeled directly to either ornithine transcarbamylase (for arginine/urea synthesis) or aspartate transcarbamylase (for pyrimidine synthesis) without diffusing into the bulk solvent. This channeling increases metabolic efficiency and prevents wasteful hydrolysis. In the hyperthermophilic archaeon Pyrococcus abyssi, carbamoyl phosphate is partitioned between the pyrimidine and arginine biosynthetic pathways, demonstrating the importance of regulated channeling.
Compartmentalization in Eukaryotes
In simple terms: In human cells, one enzyme makes carbamoyl phosphate in mitochondria for urea, and another makes it in the cytosol for pyrimidines.
Eukaryotes possess two distinct CPS enzymes: CPS1 in the mitochondrial matrix, which provides carbamoyl phosphate for the urea cycle, and CPS2 in the cytosol, which provides carbamoyl phosphate for pyrimidine biosynthesis. These pools are separate and differentially regulated. Studies in rat liver have shown that mitochondrial and cytosolic carbamoyl phosphate pools contribute differently to de novo pyrimidine synthesis, with the cytosolic pool being the primary source for UMP formation.
Allosteric Regulation by N-Acetylglutamate
In simple terms: A small molecule called N-acetylglutamate turns the mitochondrial enzyme on when amino acids are plentiful.
Mammalian CPS1 is allosterically activated by N-acetylglutamate, which is synthesized from glutamate and acetyl-CoA. This activation couples urea cycle flux to the availability of ammonia from amino acid catabolism. In contrast, CPS2 is regulated by the pyrimidine pathway enzyme CAD and by feedback inhibition from UTP. The differential regulation ensures that carbamoyl phosphate is directed to the appropriate pathway according to cellular needs.
Key Genes Involved in GO:0070409 carbamoyl phosphate biosynthetic process
The following genes and proteins are central to carbamoyl phosphate biosynthetic process (GO:0070409) and its regulation in various organisms.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CPS1 | Mitochondrial carbamoyl phosphate synthetase; catalyzes carbamoyl phosphate synthesis for urea cycle | Deficiency causes hyperammonemia; altered in cancer metabolism and radioresistance |
| CPS2 | Cytosolic carbamoyl phosphate synthetase; supplies carbamoyl phosphate for pyrimidine biosynthesis | Target for antimetabolite and anticancer drug development |
| CAD | Multienzyme complex containing CPS2, ATCase, and DHOase; channeling carbamoyl phosphate to pyrimidines | Regulated by MAPK and mTOR pathways; studied in cancer and cell cycle |
| OTC | Ornithine transcarbamylase; condenses carbamoyl phosphate with ornithine to form citrulline | Deficiency causes OTC deficiency, a urea cycle disorder |
| ASS1 | Argininosuccinate synthetase; uses citrulline and aspartate to form argininosuccinate | Downregulated in some cancers; linked to arginine auxotrophy |
| ASL | Argininosuccinate lyase; cleaves argininosuccinate to arginine and fumarate | Deficiency causes argininosuccinic aciduria |
| ARG1 | Arginase 1; hydrolyzes arginine to urea and ornithine | Marker of hepatocellular carcinoma; involved in immune suppression |
| NAGS | N-acetylglutamate synthase; produces the allosteric activator of CPS1 | Deficiency causes hyperammonemia; target for therapy |
| GLS | Glutaminase; provides ammonia for CPS1 in some contexts | Linked to cancer metabolism and glutamine dependency |
| PYCR1 | Pyrroline-5-carboxylate reductase 1; supports proline synthesis and redox balance | May influence carbamoyl phosphate demand in cancer |
| MTHFD2 | Methylenetetrahydrofolate dehydrogenase 2; supports one-carbon metabolism | Interacts with pyrimidine synthesis pathways |
| DHODH | Dihydroorotate dehydrogenase; fourth enzyme in pyrimidine synthesis | Target of teriflunomide and other inhibitors |
| UMPS | Uridine monophosphate synthetase; converts orotate to UMP | Deficiency causes orotic aciduria; linked to pyrimidine supply |
| CTPS1 | CTP synthase 1; converts UTP to CTP | Regulated by feedback and involved in lymphocyte proliferation |
| RRM2 | Ribonucleotide reductase subunit M2; converts NTPs to dNTPs | Target of gemcitabine; affects DNA synthesis |
| c-Myc | Transcription factor; regulates genes in nucleotide metabolism | Stabilized upon CPS1 deficiency, promoting radioresistance |
| mTOR | Kinase; regulates CAD and pyrimidine synthesis | Links nutrient signaling to carbamoyl phosphate demand |
| ATF4 | Transcription factor; mediates integrated stress response | May regulate CPS1 expression under stress |
How Is carbamoyl phosphate biosynthetic process Regulated?
Carbamoyl phosphate biosynthesis is regulated at multiple levels. In mammals, CPS1 is allosterically activated by N-acetylglutamate, which is produced by NAGS in response to arginine and glutamate availability. CPS2, as part of the CAD complex, is regulated by phosphorylation via MAPK and mTOR pathways, and by feedback inhibition from UTP. Additionally, the expression of CPS1 and CPS2 can be modulated by transcription factors such as ATF4 and c-Myc in response to metabolic stress and oncogenic signals. In bacteria and archaea, the pathway is controlled by arginine and pyrimidine availability, often through transcriptional attenuation and enzyme channeling.
carbamoyl phosphate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CPS1 | Hyperammonemia; cancer metabolism; radioresistance | CPS1 knockout hepatocytes; patient-derived iPSCs; xenograft models |
| CPS2/CAD | Pyrimidine biosynthesis disorders; cancer proliferation | CAD knockout cell lines; CRISPR knock-in of patient mutations |
| OTC | Ornithine transcarbamylase deficiency | Otc knockout mice; liver-specific KO |
| ASS1 | Argininosuccinate synthetase deficiency; arginine auxotrophy in cancer | ASS1 KO cancer cell lines; arginine deprivation studies |
| c-Myc | Radioresistance; oncogenesis | c-Myc transgenic models; CPS1-deficient HCC xenografts |
CPS1 Deficiency and Hyperammonemia
Biallelic mutations in CPS1 cause carbamoyl phosphate synthetase 1 deficiency, an autosomal recessive urea cycle disorder characterized by hyperammonemia, lethargy, and vomiting in neonates. Without functional CPS1, ammonia cannot be converted to urea, leading to toxic accumulation. Treatment includes low-protein diet, ammonia scavengers, and in severe cases liver transplantation. Research into small-molecule chaperones and gene therapy is ongoing.
CPS1 in Cancer Metabolism and Radioresistance
CPS1 expression is upregulated in some cancers, including KRAS/LKB1-mutant lung adenocarcinoma, where it maintains pyrimidine pools and supports DNA synthesis and proliferation. In hepatocellular carcinoma, loss of CPS1 promotes radioresistance through deubiquitination and stabilization of c-Myc, suggesting that CPS1 status may predict response to radiotherapy. These findings highlight the potential of targeting carbamoyl phosphate biosynthesis in precision oncology.
Pyrimidine Biosynthesis Disorders
Defects in the pyrimidine branch that consumes carbamoyl phosphate can cause orotic aciduria, a rare metabolic disorder characterized by megaloblastic anemia and developmental delay. While the primary defect is in UMP synthase, the availability of carbamoyl phosphate from CPS2 influences flux through the pathway. Studies in rat liver have clarified the distinct roles of mitochondrial and cytosolic carbamoyl phosphate pools in de novo pyrimidine synthesis.
From carbamoyl phosphate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CPS1 loss affect pyrimidine pools and DNA synthesis? | CPS1 knockout cancer cell lines (e.g., A549, H460) with metabolomics and BrdU incorporation |
| How does CPS1 deficiency alter radioresistance? | CPS1 knockout hepatocellular carcinoma cells followed by irradiation and clonogenic survival |
| What is the impact of CPS1 point mutations on enzyme activity? | CRISPR knock-in of patient-derived missense mutations in cell lines; enzyme kinetics |
| Can CPS1 overexpression drive proliferation? | CPS1 overexpression in non-transformed cells; proliferation and colony formation assays |
| How is carbamoyl phosphate channeled to pyrimidines vs. urea? | Tagged knock-in of CPS1 and CPS2 with proximity labeling; metabolic tracing |
| What is the role of N-acetylglutamate in CPS1 regulation? | NAGS knockout models; allosteric activation assays |
How to Study the carbamoyl phosphate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Carbamoyl phosphate, citrulline, pyrimidines | Quantify pathway flux in cells and tissues |
| 13C-bicarbonate tracing | De novo carbamoyl phosphate synthesis | Measure metabolic flux in cancer cells |
| CPS activity assay | Enzymatic conversion of substrates to carbamoyl phosphate | Assess mutant enzyme kinetics |
| CRISPR knockout | Loss-of-function phenotypes | Determine gene essentiality |
| CRISPR knock-in | Patient-specific mutations | Model inherited disorders |
| RNA-seq | Transcriptional changes | Identify regulatory networks |
| Proteomics | Protein abundance and modifications | Discover c-Myc stabilization |
| Clonogenic survival assay | Radioresistance | Test CPS1 role in DNA repair |
Metabolomics and Isotope Tracing
Mass spectrometry-based metabolomics can quantify carbamoyl phosphate and downstream metabolites such as citrulline, arginine, and pyrimidine nucleotides. Stable isotope tracing with 15N-ammonia or 13C-bicarbonate allows researchers to measure flux through GO:0070409 in cells and tissues. These methods are essential for linking CPS1 activity to urea cycle and pyrimidine output.
Enzyme Activity Assays
Carbamoyl phosphate synthetase activity can be measured in cell lysates or purified enzyme preparations by coupling the reaction to ornithine transcarbamylase and measuring citrulline formation. Radioactive or colorimetric assays are commonly used. Such assays help determine the impact of mutations or inhibitors on catalytic efficiency.
CRISPR-Cas9 Genome Editing
CRISPR knockout, knock-in, and point mutation models enable precise interrogation of CPS1, CPS2, and related genes. Knockout cells reveal loss-of-function phenotypes, while knock-in of patient mutations recapitulates disease-specific defects. These models are combined with metabolic and proliferation assays to establish causality.
Transcriptomics and Proteomics
RNA-seq and quantitative proteomics can reveal changes in gene expression and protein abundance upon modulation of carbamoyl phosphate biosynthesis. For example, CPS1 deficiency alters c-Myc stability and downstream gene expression. These global approaches identify compensatory pathways and biomarkers.
How CRISPR Can Be Used to Study GO:0070409 carbamoyl phosphate biosynthetic process
Knockout
CRISPR-Cas9 knockout of CPS1 or CPS2 generates cell lines that completely lack carbamoyl phosphate biosynthesis. These models are used to study metabolic dependencies, pyrimidine auxotrophy, and sensitivity to radiation or chemotherapy. For example, CPS1 knockout in KRAS/LKB1-mutant lung cancer cells reduces pyrimidine pools and impairs DNA synthesis.
Point Mutation
Point mutations identified in patients with CPS1 deficiency can be introduced via CRISPR-mediated homology-directed repair. These knock-in models allow researchers to study the functional impact of specific missense or nonsense mutations on enzyme activity, stability, and allosteric regulation. They are valuable for genotype-phenotype correlations and drug testing.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous CPS1 or CPS2 locus enables real-time imaging, immunoprecipitation, and proximity labeling. Tagged knock-in models help track protein localization, interactions, and channeling to downstream enzymes without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CPS1 can model gain-of-function states observed in cancers. Overexpression studies help determine whether increased carbamoyl phosphate biosynthesis is sufficient to drive proliferation, pyrimidine pool expansion, or resistance to therapy.
How EDITGENE Supports carbamoyl phosphate biosynthetic process Research
Researchers studying carbamoyl phosphate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in metabolic rewiring, disease progression, or therapy response. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for carbamoyl phosphate biosynthetic process research.
Frequently Asked Questions About carbamoyl phosphate biosynthetic process
What is carbamoyl phosphate biosynthetic process?
It is the set of biochemical reactions that produce carbamoyl phosphate, a key intermediate in the urea cycle and pyrimidine biosynthesis, defined by GO:0070409.
What genes are involved in carbamoyl phosphate biosynthetic process?
Key genes include CPS1, CPS2, CAD, OTC, NAGS, and ASS1, among others.
What is the role of CPS1 in carbamoyl phosphate biosynthesis?
CPS1 is the mitochondrial enzyme that catalyzes carbamoyl phosphate synthesis for the urea cycle, using ammonia and bicarbonate.
How is carbamoyl phosphate biosynthetic process regulated?
It is regulated by allosteric activation (N-acetylglutamate for CPS1), phosphorylation (CAD), and feedback inhibition by pyrimidines.
What diseases are associated with defects in carbamoyl phosphate biosynthesis?
CPS1 deficiency causes hyperammonemia; altered CPS1 expression is linked to cancer metabolism and radioresistance.
Why is carbamoyl phosphate important for pyrimidine synthesis?
Carbamoyl phosphate provides the carbamoyl group for the pyrimidine ring, essential for UMP and downstream nucleotides.
How can I study carbamoyl phosphate biosynthetic process in the lab?
Use CRISPR knockout/knock-in models, metabolomics, enzyme activity assays, and isotope tracing.
What is the difference between CPS1 and CPS2?
CPS1 is mitochondrial and supplies the urea cycle; CPS2 is cytosolic and supplies pyrimidine biosynthesis.
Can carbamoyl phosphate biosynthesis be targeted for cancer therapy?
Yes, CPS1 is a metabolic vulnerability in KRAS/LKB1-mutant lung cancer and may be targeted in other cancers.
What model systems are used to study GO:0070409?
Common models include cancer cell lines, primary hepatocytes, knockout mice, and patient-derived iPSCs.
Conclusion
Carbamoyl phosphate biosynthetic process (GO:0070409) is a fundamental metabolic pathway that bridges nitrogen disposal and nucleotide synthesis. Its dysregulation contributes to inherited hyperammonemia and cancer progression, making it a compelling target for therapeutic intervention. Advances in CRISPR genome editing, metabolomics, and structural biology continue to illuminate the mechanistic details and disease relevance of this pathway. Researchers equipped with precise cell models and analytical tools are well positioned to translate these insights into clinical benefit.
References
- 1. Kim J et al.. 2017. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.. Nature 546(7656):168-172 PMID: 28538732
- 2. Meijer AJ et al.. 1985. Control of ureogenesis.. Eur J Biochem 148(1):189-96 PMID: 3979393
- 3. Zhang L et al.. 2023. Unraveling the therapeutic potential of carbamoyl phosphate synthetase 1 (CPS1) in human diseases.. Bioorg Chem 130:106253 PMID: 36356370
- 4. Purcarea C et al.. 1999. Channeling of carbamoyl phosphate to the pyrimidine and arginine biosynthetic pathways in the deep sea hyperthermophilic archaeon Pyrococcus abyssi.. J Biol Chem 274(10):6122-9 PMID: 10037695
- 5. Raushel FM et al.. 1998. Carbamoyl phosphate synthetase: a crooked path from substrates to products.. Curr Opin Chem Biol 2(5):624-32 PMID: 9818189
- 6. Makoff AJ et al.. 1978. Genetics and biochemistry of carbamoyl phosphate biosynthesis and its utilization in the pyrimidine biosynthetic pathway.. Microbiol Rev 42(2):307-28 PMID: 353478
- 7. Zhang S et al.. 2023. Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc.. Int J Radiat Oncol Biol Phys 115(5):1244-1256 PMID: 36423742
- 8. Pausch J et al.. 1985. Hepatic carbamoyl phosphate metabolism. Role of cytosolic and mitochondrial carbamoyl phosphate in de novo pyrimidine synthesis.. Eur J Biochem 150(1):189-94 PMID: 4018077
